Archive

Tag: Andexanet Alfa

Andexxa Vs 4F-PCC in ICH: An Ongoing Debate

BACKGROUND: Direct oral anticoagulants (DOACs) such as rivaroxaban [Xarelto] and apixaban [Eliquis] have become more prevalent in the aging population and are associated with intracranial bleeding at rates up to 4.2%. (Xian 2019) 4-Factor Prothrombin Complex Concentrates (4F-PCC), or K-Centra, …

Read More
NeurologyTrauma

Andexanet Alfa Vs. Four-Factor PCC: Is Andexanet Alfa Worth The Hype?

Background: Oral factor Xa inhibitors (FXi) have been associated with major and fatal bleeding events, including intracranial hemorrhage (ICH). In randomized controlled trials, both rivaroxaban and apixaban are associated with ICH at rates that range from 0.1 to 4% (Agnelli …

Read More
Hematology and OncologyNeurologyTrauma

ANNEXA-4: Andexanet Alfa and Factor Xa Inhibitors

Background: Over the past few years we have seen a surge in the use of oral Factor Xa inhibitors (apixaban, rivaroxaban etc) for anticoagulation.  The reason for this is the ease of use, standard dosing with no levels to check and …

Read More
Hematology and Oncology

Sponsored

0